Loading clinical trials...
Loading clinical trials...
A Two-week, Randomised, Double-blind Study Assessing the Onset of Effect Questionnaire Administered Daily Versus Weekly in Adult Subjects (≥ 18 Years) With Mild to Moderate Asthma, Receiving SYMBICORT® pMDI 80/4.5 μg x 2 Actuations Twice Daily or Budesonide HFA pMDI 80 μg x 2 Actuations Twice Daily
The purpose of this study is to demonstrate whether subjects respond similarly to the Onset of Effect Questionnaire (OEQ) using a 1 week recall period versus a 1 day recall period.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Research Site
Tuscumbia, Alabama, United States
Research Site
Fort Smith, Arkansas, United States
Research Site
Long Beach, California, United States
Research Site
Orange, California, United States
Research Site
Riverside, California, United States
Research Site
Sacramento, California, United States
Research Site
San Diego, California, United States
Research Site
San Jose, California, United States
Research Site
Colorado Springs, Colorado, United States
Research Site
Denver, Colorado, United States
Start Date
March 1, 2007
Completion Date
August 1, 2007
Last Updated
January 24, 2011
123
ACTUAL participants
Budesonide/formoterol pMDI
DRUG
Budesonide HFA pMDI
DRUG
Lead Sponsor
AstraZeneca
NCT07486401
NCT07219173
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT02327897